Ketek

Ketek is a prescription antibiotic used for cases of acute bacterial illnesses such as chronic bronchial infections, pneumonia, sinusitis and lung infections. Its use has come under scrutiny after multiple cases of liver toxicity were reported associated with the drug.

In March 2006, the Annals of Internal Medicine published an article documenting the cases of three patients who suffered “drug-induced” liver toxicity believed the result of Ketek. Since then, an FDA safety review found at least 53 reports of serious liver toxicity associated with Ketek. Additional FDA reports associate liver problems with the drug. The FDA recommended in May 2006 that Ketek include the highest warning level, the black-box warning, to inform users about the possibility of severe liver damage. An FDA Advisory Committee discussed the safety and efficacy of Ketek during a hearing Dec. 14–15, 2006, and decided the drug should no longer be prescribed for certain illnesses.

If your doctor has prescribed Ketek, be certain you are completely informed about the drug’s adverse effects. Both the drug manufacturer, Sanofi-Aventis and the FDA have posted information with precautions and warnings of liver damage and other serious side effects. Contact your doctor immediately if you have been taking Ketek and suspect you have symptoms of liver damage.

To learn more about legal claims relating to Ketek, you should consult an attorney who practices in the area of drugs and medical devices.

Defective Drugs & Medical Devices Topics

Latest Articles

Deficiency Judgment and Foreclosures

A person borrowing money to buy a home assumes the loan is secured by the mortgage lien on the house…

Read More 07 Nov 2019, Thursday

How Can a Lawyer Help You Defend Against Foreclosure?

If you fall behind on your mortgage payments, your house might end up in foreclosure. However, there…

Read More 21 Oct 2019, Monday

The Google Antitrust Investigation

What’s Happening and How It May Potentially Affect Access to Legal Services Earlier this month…

Read More 25 Sep 2019, Wednesday